Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5] Pyrazino [2, 1-B] Oxazepin-8-Olate - EP3321270
EP3321270
- Application Number
- EP17204116A
- Filing Date
- Jun 19, 2015
- Status
- Granted And Under Opposition
- Nov 1, 2024
- Grant Date
- Dec 4, 2024
- External Links
- Slate, Register, Google Patents
Bibliography
The patent EP3321270B1 was granted to Gilead Sciences on Dec 4, 2024 following the initial filing on Jun 19, 2015 under the application number EP17204116A . The current legal status of the patent is Granted And Under Opposition.
Patent Summary
Patent Family
Patent Oppositions (5)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents